source
- Marengo's bispecific antibody invikafusp alfa shows tumor shrinkage in 8 cancer types in Phase 2Marengo Therapeutics presented Phase 2 data for its bispecific antibody invikafusp alfa at the European Society for Medical Oncology meeting in Madrid. The study, part of the Start-001 first‑in‑hum…
- Roche's Genentech reports 43% reduction in kidney damage marker in phase 3 IgA nephropathy trialRoche Genentech disclosed detailed results from its phase 3 IMAgINATION trial of the antisense oligonucleotide sefaxersen in patients with IgA nephropathy. The trial showed a 43.1% greater reducti…Fierce Biotech · 18d agoPositive readoutPositive